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Abbreviations 
 
 
Bcl-2 B-cell chronic lymphocytic leukemia/lymphoma 2 
COX cyclooxygenase 
cPGES cytosolic prostaglandin E synthase 
CRE cAMP response element 
DAPI 4',6-diamidino-2-phenylindole 
DHHDP dehydrohexahydroxydiphenoyl 
DMSO dimethyl sulfoxide 
ESI-MS electrospray ionization mass spectrometry 
Et2O diethyl ether 
EtOAc ethyl acetate 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
HE hematoxylin and eosin 
HEK human embryonic kidney 
HETE hydroxyeicosatetraenoic acid 
HPETE hydroperoxyeicosatetraenoic acid 
IL interleukin 
IMQ imiquimod 
iNOS inducible nitric oxide synthase 
KPB potassium phosphate buffer 
Krt1 keratin 1 
LOX lipoxygenase 
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LT leukotriene 
mPGES-1 microsomal prostaglandin E synthase-1 
mPGES-2 membrane-bound prostaglandin E synthase-2 
MRM multiple reaction monitoring 
n-BuOH water-saturated n-butanol 
NF-B nuclear factor-B 
NSAIDs non-steroidal anti-inflammatory drugs 
PG prostaglandin 
RBL rat basophilic leukemia 
RRP red-kerneled rice proanthocyanidin 
Th17 T helper 17 
TNF tumor necrosis factor 
TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick end 
labeling  
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Chapter I 
 
 
Introduction 
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 Japan has been a super-aged society with more than 21% of the population of 65 
years or older. Chronic diseases that increase with aging are triggered by the underlying 
chronic inflammation. Therefore, the key to a long and healthy life is to prevent chronic 
inflammation. 
Prostaglandin (PG) E2 and leukotrienes (LTs) play a key role in pro-
inflammation. PGE2 is widely distributed in many tissues and organs, and contributes to 
maintenance of homeostasis such as awakening, bone metabolism, and inhibition of 
gastric secretion. On the other hand, it regionally causes or promotes various 
pathophysiological reactions including fever, pain, and tumorigenesis 1–4. PGE2 is 
biosynthesized from arachidonic acid by cyclooxygenase (COX) and PGE synthase 
(PGES) 1(Fig. 1). The COX-2 and microsomal PGES-1 (mPGES-1) are functionally 
coupled 5 and induced by pro-inflammatory cytokines, growth factors, and endotoxins. 
Subsequently, the hyperproduced PGE2 causes several inflammatory disorders 6. 
 
 
Fig. 1. Arachidonic acid cascade. 
These lipid mediator bind to specific receptors and exerts various physiological effects. 
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In clinical treatment, COX inhibitors called non-steroidal anti-inflammatory 
drugs (NSAIDs) are used widely as antipyretic analgesic drugs. However they have side 
effects, because they reduce not only pathogenetic PGE2 but also the other important 
prostanoids for maintaining homeostasis. Though COX-2 selective inhibitors have been 
developed to reduce the side effects, even they increase the risk of cardiovascular disease, 
because COX-2 inhibition in vascular endothelial cells reduces PGI2 as an anti-platelet 
aggregation factor 7–9. In fact, it is demonstrated experimentally that COX-2-deficient 
mice, but not mPGES-1-deficient mice, show accelerated thrombogenesis and elevated 
blood pressure 10. Thus, there is a strong demand for development of an effective and safe 
alternative approach to use of COX inhibitors, and mPGES-1 is thought to represent a 
possible therapeutic target for inflammatory disorders 2. Previously it was demonstrated 
that Dioscorea japonica extract reduced PGE2 production in cancer and inflammatory 
cells11, and exhibited the preventive effects on skin carcinogenesis 12, however, the effects 
were resulted by the suppressed COX-2 and mPGES-1 expression. Furthermore, it will 
be important to explore substances specifically targeting mPGES-1 from natural products. 
5-lipoxygenase (LOX) is a key enzyme in the production of LTs, and dual-
functionally catalyzes the oxygenation of arachidonic acid to 5- 
hydroperoxyeicosatetraenoic acid (5-HPETE) and its dehydration to LTA4 (Fig. 1). LTA4 
is then converted to LTB4 by LTA4 hydrolase and LTC4 by LTC4 synthase. LTB4 promotes 
chemotaxis and activates leukocytes, whereas LTC4 and the metabolites LTD4 and LTE4 
are involved in bronchoconstriction, mucus secretion, and in the pathogenesis of asthma. 
Zileuton, the only 5-LOX inhibitor presently available for clinical use, has side effects 
such as liver toxicity 13,14. Therefore, novel inhibitors of 5-LOX without side effects are 
needed to improve and prevent chronic inflammatory disorders including psoriasis. 
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In this study, functional ingredients derived from natural products targeting 
mPGES-1 and 5-LOX were explored. Chapter II describes that ellagitannins from Punica 
granatum leaves down-regulated mPGES-1 expression in human non-small cell lung 
carcinoma A549 cells, and induced cancer cells to apoptosis 15. Chapter III describes that 
red-kerneled rice proanthocyanidin (RRP) inhibited mPGES-1 and 5-LOX, and improved 
the psoriasis-like skin inflammation 16.  
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Chapter II 
 
 
Ellagitannins from Punica granatum leaves 
suppress microsomal prostaglandin E 
synthase-1 expression and induce lung 
cancer cells to undergo apoptosis 
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Punica granatum, known commonly as pomegranate, and various parts of this 
plant are used in traditional medicine. For example, in Chinese medicine, the pericarps 
are used as antidiarrhetic, hemostatic, and vermifuge agents; in Unani medicine, the 
flowers are used as a dietary supplement to treat diabetes 17; and, in Ayurvedic medicine, 
the bark and roots are considered to have anthelmintic properties 18. Moreover, there are 
a few reports of pomegranate leaves having anti-inflammatory effects 19,20; however, the 
active substances and the mechanism of action are not yet fully understood.  
In this study, it was demonstrated that granatin A and granatin B, abundant in 
pomegranate leaves, and the structural analog, geraniin, specifically down-regulated 
mPGES-1 expression, and they had effects on inflammation and carcinogenesis in human 
lung carcinoma model A549 cells. 
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MATERIALS AND METHODS 
 
 
Preparation of extract and ellagitannins 
70% aqueous acetone extract of Photinia×fraseri, Siraitia grosvenorii, Punica 
granatum leaf, and Magnolia coco, and ellagitannins were kindly provided by Prof. 
Hideyuki Ito. The ellagitannins were extracted by reference to previous reports 21,22. 
Pomegranate leaves (590 g) were homogenized with 70% aqueous acetone, and the 
homogenate was filtered and concentrated to obtain the acetone extract (150 g). A part of 
the acetone extract (20 g) was extracted with diethyl ether (Et2O), ethyl acetate (EtOAc), 
and water-saturated n-butanol (n-BuOH) each 1.8 L to yield the Et2O extract (163 mg), 
EtOAc extract (6.1 g), n-BuOH extract (5.8 g), and water soluble portion (5.6 g). The 
EtOAc extract was column chromatographed over TOYOPEARL® HW-40 (Tosoh Co., 
Tokyo, Japan), yield granatin A (252 mg, 98.3% purity) and granatin B (3.3 g, 97.1% 
purity). Geraniin (97.0% purity) was isolated using the method described previously 23. 
The dried extracts and ellagitannins were re-dissolved in dimethyl sulfoxide (DMSO) or 
ethanol and added to the cell culture medium. 
 
Cell culture  
The human non-small cell lung carcinoma cell line A549 (ATCC CCL-185) was 
obtained from RIKEN BioResource Center (Tsukuba, Japan). The cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum, 100 
units/ml penicillin, and 100 g/ml streptomycin. The cells were maintained at 37 °C in a 
humidified atmosphere of 95% air and 5% CO2. A549 cells treated with 0–10 g/ml 
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acetone extract or 0–10 M granatin A, granatin B, and geraniin in ethanol, or the other 
extracts in DMSO or were added only vehicle as a control. The viability of the cells was 
measured using the CellTiter-Glo® 2.0 Assay (Promega, Madison, WI. USA). 
 
Real-time quantitative PCR 
After 24 h treatment in either the presence or absence of 10 ng/ml IL-1 A549 
cells were collected, the total RNA was isolated using the acid guanidinium thiocyanate 
procedure, and cDNA was prepared using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, LLC, Foster City, CA. USA). Real-time PCR was 
performed using SsoAdvancedTM Universal SYBR® Green Supermix (Bio Rad Labs., 
Hercules, CA. USA) on the StepOnePlusTM Real-Time PCR System (Applied Biosystems, 
LLC, Foster City, CA. USA), and primer pairs, as follows: PTGES (mPGES-1), 5′-
TGATCACACCCACAGTTGAGC-3′ (forward) and 5′-TGATGATGGCCACCACGTA 
-3′ (reverse); PTGS2 (COX-2), 5′-TGCATTCTTTGCCCAGCACT-3′ (forward) and 5′-
AAAGGCGCAGTTTACGCTGT-3′ (reverse); TNF (TNF), 5′-GGACCTCTCTCTAA 
TCAGCCCTC-3′ (forward) and 5′-TCGAGAAGATGTCTGACTGCC-3′ (reverse); 
NOS2 [inducible nitric oxide synthase (iNOS)], 5′-TGCAGACACGTGCGTTACTCC-3′ 
(forward) and 5′-GGTAG CCAGCATAGCGGATG-3′ (reverse); BCL2 [B-cell chronic 
lymphocytic leukemia/lymphoma 2 (Bcl-2)], 5′-AGTACCTGAACCGGCACCT-3′ 
(forward) and 5′-GCCGTACAGTTCCACAAAGG-3′ (reverse); GAPDH 
[glyceraldehyde 3-phosphate dehydrogenase (GAPDH)], 5′-CGAGATCCCTCCAAAA 
TCAA-3′ (forward) and 5′-TTCACACCCATGACGAACAT-3′ (reverse). The data were 
normalized to the GAPDH expression level. 
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Western blotting 
Microsomal fractions (20 g) from A549 cells, treated for 48 h either with or 
without 10 ng/ml IL-1 were electrophoresed on SDS-polyacrylamide gels and then 
transferred them onto Immobilon-P membrane (Millipore, Burlington, MA. USA). 
Following treatment with blocking reagent (Roche, Penzberg, Germany), the membrane 
was incubated with either rabbit anti-mPGES-1 IgG (1:1000, Novus Biologicals, LLC, 
Centennial, CO. USA), rabbit anti-COX-2 IgG (1:100, Immuno-Biological Laboratories 
Co., Ltd., Gumma, Japan) or rabbit anti--actin IgG (1:1000, Cell Signaling Technology, 
Boston, MA. USA). It was visualized the immunoreactive proteins using BM 
chemiluminescence Western blotting kit (Roche). The densities of each of the protein 
bands were assessed as described previously 11. 
 
mPGES-1 activity 
The cells were incubated for 24 h in either the presence or absence of 10 ng/ml 
IL-1, 10 M granatin A or granatin B, or geraniin, as indicated. After the cells were 
scraped off the dishes and disrupted by sonication, the microsomal fractions were isolated 
by centrifugation at 100,000 xg. The microsomal fractions were used as the enzyme 
source.  mPGES-1 activity was initiated by adding 40 M PGH2 in 100 mM KPB buffer 
(pH 7.2) with 2.5 mM glutathione for 1 min at 24 °C. The reaction was terminated using 
100 mM FeCl2 / 0.5 M citric acid, and 2.5 nmol of PGB2 were added as an internal 
standard. The PGE2 produced was analyzed via reverse-phase HPLC using COSMOSIL 
5C18-MS-II column (5 m particle, 4.6×250 mm, Nacalai Tesque, Kyoto, Japan) with a 
solvent system of acetonitrile/water/acetic acid (40:60:0.01, v/v). The absorption 
spectrum was monitored at 192 nm continuously, using the Waters 2489 UV/Visible 
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detector. The PGE2 was quantified by comparing of the peak areas with that of an internal 
standard. 
 
Enzyme immunoassay 
 Following 24 h treatment to A549 cells (2×104cells/well) either with or without 
10 ng/ml IL-1, 10 M granatin A or granatin B, or geraniin, arachidonic acid (10 M) 
was added to the culture medium of the cells. After 30 min incubation with the 
arachidonic acid, PGE2 concentration was measured in the medium via an enzyme 
immunoassay using the PGE2 ELISA Kit (Cayman Chemical Co. Ann Arbor, MI. USA), 
according to the manufacturer’s instructions. 
 
TUNEL assay 
After 48 h treatment by the above concentrations of the ellagitannins, terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was 
carried out to identify the extent of DNA fragmentation in the A549 cells, using the 
Peroxidase In Situ Apoptosis Detection Kit (EMD Millipore, Billerica, MA. USA), as 
described previously 11. The number of TUNEL-positive cells was counted in 10 separate 
observations with a light microscope (ECLIPSE 80i; Nikon Co., Tokyo, Japan). 
 
Statistics 
 The data were analyzed statistically using Dunnett’s post-hoc test at a 
significance level of p < 0.01.  
14 
 
RESULTS 
 
 
COX-2 and mPGES-1 are expressed constitutively in lung carcinoma A549 cells, 
and approximately 10-fold and 20-fold expression was induced by IL-1 (data not shown). 
In IL-1 stimulatedA549 cells, mPGES-1 suppression of some samples derived from 
natural products was screened, and pomegranate leaf extract showed the dose-dependent 
effect without COX-2 suppression among them. (Fig. 2). Pomegranate leaf extract 
(acetone extract) suppressed the expression of mPGES-1 in a dose-dependent manner (0-
10 g/mL); however, it tended to induce COX-2 expression in the cells (Fig. 3A). Then, 
the sequent some fractions extracted by the liquid–liquid method described in the 
Materials and Methods section and in Fig. 3D. Following addition of each fraction (10 
g/ml) to the culture medium of A549 cells, the EtOAc and n-BuOH fractions suppressed 
mPGES-1 expression strongly in a dose-dependent manner (Fig. 3B and C). The 
 
Fig. 2. Screening for suppression of PTGES (mPGES-1) expression in A549 cells. 
Changes in mRNA levels of PTGES (open bar) and PTGS2 (closed bar) by treatment with acetone 
extract of Photinia×fraseri, Siraitia grosvenorii, Punica granatum leaf, and Magnolia coco were 
analyzed by real-time PCR, as described in the Materials and Methods section. The values are 
represented as a relative value against control without extract treatment and represent mean ± SEM 
(n = 3). *p < 0.01, compared with control without extract treatment. 
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ellagitannins granatin A and granatin B (Fig. 4) were identified as major components in 
the EtOAc and n-BuOH fractions 24–26. Their structural analog geraniin is known as being 
a main polyphenolic component of Geranium thunbergii, a medicinal plant with an 
antidiarrheic effect 27,28. These ellagitannins contain a dehydrohexahydroxydiphenoyl 
(DHHDP) group, which has been reported to have anti-inflammatory effects 29,30. 
Therefore, these ellagitannins were listed as candidate ingredients to suppress mPGES-1.  
 
Fig. 3. Effect of pomegranate leaf extract on the mRNA expression of PTGES (mPGES-1) and 
PTGS2 (COX-2) in A549 cells. 
Changes in mRNA levels of PTGES (open bar) and PTGS2 (closed bar) by treatment with acetone 
extract (0–10 g/ml, A); each extract from pomegranate leaf (10 g/ml, B), and EtOAc and n-
BuOH extracts (C) was analyzed by real-time PCR, as described in the Materials and Methods 
section. The scheme of extraction and fractionation from Punica granatum leaves is shown in D. 
The values are represented as a relative value against control without extract treatment and 
represent mean ± SEM (n = 4; A, B, n = 3; C). *p < 0.01, compared with control without extract 
treatment. 
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Granatin A, granatin B, and geraniin suppressed the mRNA expression of 
mPGES-1 in a dose-dependent manner (Fig. 5A). Treatment with 10 M granatin A, 
granatin B, and geraniin decreased mRNA levels of mPGES-1 significantly, to 23%, 15%, 
and 33%, respectively, compared to the control without treatment, whereas they did not 
affect those of COX-2 (Fig. 5A). Granatin A, granatin B, and geraniin also suppressed 
the expression of mPGES-1 protein (Fig. 5B), and reduced the ratio of mPGES-1 against 
COX-2 to 75%, 53%, and 65%, respectively, compared to control without treatment (IL-
1β+/vehicle in Fig. 5B). In particular, granatin B reduced the ratio by less than the level 
of control cells without IL-1β stimulation (IL-1β−/vehicle in Fig. 5B). IL-1 stimulation 
increased the mPGES-1 activity of the microsomal fraction in A549 cells approximately 
4-fold (200 nmol·min−1·mg−1) (Fig. 5C), and 24 h treatments with 10 M of granatin A, 
granatin B, and geraniin decreased the activity to 17%, 16%, and 11%, respectively, 
which activities were lower than the activity without IL-1 stimulation. It was also 
confirmed that IL-1 stimulation in the culture medium of A549 cells increased PGE2 
release to approximately 12-fold (5 ng·1×104cells−1) and that pretreatment with 10 M of 
granatin A, granatin B, and geraniin decreased PGE2 release significantly, to 65%, 45%, 
 
Fig. 4. Chemical structure of granatin A, granatin B, and geraniin. 
The abundant compounds in EtOAc and n-BuOH extracts were identified as granatin A and 
granatin B. Chemical structures of the ellagitannins and their structural analog geraniin are shown. 
The dashed lines indicate the DHHDP group. 
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and 50%, respectively (Fig. 5D). To exclude the possibility that the cytotoxic action of 
granatin A, granatin B, and geraniin was responsible for suppressing gene expression, it 
was examined the effect of these ellagitannins on cell viability. Under the experimental 
conditions described above, there was no significant change in cell viability (Fig. 5E). 
Inflammation-related genes, tumor necrosis factor  (TNF), and iNOS, were 
down-regulated in a dose-dependent manner by the addition of granatin A, granatin B, 
and geraniin, excluding the expression of TNF at 10 M geraniin (Fig. 6A). Further, the 
ellagitannins suppressed anti-apoptotic factor Bcl-2 markedly in a dose-dependent 
 
Fig. 5. Effects of granatin A, granatin B, and geraniin on mPGES-1 and COX-2 expression. 
Real-time PCR (A) and western blotting (B) were used to measure mRNA and protein expression 
of PTGES (mPGES-1) and PTGS2 (COX-2), respectively. The mPGES-1 protein band density was 
corrected with COX-2; the ratio is represented as a relative value against the IL-1 (+) control in 6 
separate analyses (lower graph in B). mPGES-1 activity after treatment with either granatin A, 
granatin B, or geraniin (10 M) was measured, as described in the Materials and Methods section 
(C). PGE2 released in the culture medium of A549 cells was quantified by enzyme immunoassay 
(D). Cell viability was assessed after 24 h using the CellTiter-Glo® 2.0 Assay (E). The values are 
represented as a relative value against control cells and represent mean ± SEM (n = 4; A, C, E, n = 
3; D, n = 6; B). *p < 0.01, compared with control without treatment with ellagitannins. 
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manner (Fig. 6B). Treatment with granatin A, granatin B, or geraniin for 48 h increased 
in situ apoptotic positive cells with the TUNEL method, and the percentage of positive 
cells was high in granatin B, geraniin, and granatin A, in that order; however, this was 
hardly observed in the control cells (Fig. 6C). In lung carcinoma A549 cells, it has been 
reported decrease in PGE2 production leads cells to apoptosis and anti-inflammation 11,31; 
thus, our finding suggests that the apoptosis of the A549 cells was due to suppression of 
mPGES-1 by the ellagitannins. These findings are consistent with previous reports that 
 
Fig. 6. Changes in mRNA expression of TNF (TNF), NOS2 (iNOS) (A) and BCL2 (Bcl-2) 
(B), and in situ detection of apoptotic cells (C) after treatment with granatin A (shaded bar), 
granatin B (closed bar), and geraniin (hatched bar). 
The values are represented as a relative value against control cells, and they represent mean ± SEM 
(n = 4; A, B). *p < 0.01, compared with control without treatment with ellagitannins. In situ 
apoptotic cells were detected by the TUNEL method, as described in the Materials and Methods 
section. The scale bar indicates 10 m. 
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granatin B 32 and geraniin 33 induce cancer cell apoptosis and have anti-cancer activity, 
and our present study added more information on the mechanism of involvement of 
ellagitannins in the regulation of mPGES-1.  
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DISCUSSION 
 
 
The mechanisms of multiple signal transduction regulate pro-inflammation and 
carcinogenesis. TNFis a well-known inflammatory cytokine with pleiotropic actions in 
tumorigenesis, inflammation, and other disorders through specific cell surface receptors; 
therefore, it is a potent therapeutic target, and anti-TNF agents have, in fact, been 
approved 34. The present findings showed that ellagitannins with the DHHDP group 
suppressed TNF expression, suggesting that they are anti-inflammatory. Nuclear factor-
B (NF-B) acting downstream of TNF receptors and toll-like receptors is a potent 
transcriptional factor of COX-2 and iNOS. The COX-2 promoter not only has an NF-B 
site but also an CCAAT/enhancer-binding protein (C/EBP) site, cAMP response element-
1 (CRE-1), E-box, and AP-1 as transcriptional response elements, and these elements are 
conserved across different species 35,36. On the other hand, the mPGES-1 promoter does 
not have binding sites for NF-B and CRE contributing to COX-2 induction, suggesting 
that the inducible mechanism of mPGES-1 is distinct from that of COX-2 37. In this study, 
the ellagitannins down-regulated mPGES-1 and iNOS but not COX-2. This suggests that 
the ellagitannins have diverse influences on the different signals instead of NF-B, and, 
thus, may down-regulate TNF, iNOS, and mPGES-1 without side effects by COX-2 
blockage. C. Lee et al. reported that granatin B reduces PGE2 production by suppressing 
the expression of COX-2 protein in LPS-stimulated RAW264.7 cells 30; their findings are 
different from our data. One reason for this may be related either to the CRE-2 element 
being found in mice but not in humans 35,36, or the possibility that the ellagitannins have 
the other indirect regulation to COX-2 expression. C. Lee et al. did not study the effects 
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on mPGES-1 expression, and so this is the first report that the ellagitannins, including 
granatin B, down-regulated mPGES-1 expression and decreased PGE2 production. 
Curcumin 38, diosgenin 12, sulforaphane 39, and sinomenine 40 have been reported 
to suppress the expression of mPGES-1, although there have been only a few reports of 
phytochemicals down-regulating mPGES-1. Curcumin and diosgenin affect not only 
mPGES-1 but also COX-2, and several phytochemicals down-regulating COX-2 have 
been reported 41. Granatin A, granatin B, and geranin suppressed mPGES-1 expression 
more strongly than established phytochemicals such as sulforaphane and sinomenine. 
These ellagitannins can be expected to be both efficacious and safe, without the side 
effects caused by COX inhibition. 
In conclusion, it is suggested that part of the mechanism of anti-inflammatory and 
anti-tumor effects by DHHDP group-containing ellagitannins, including granatin A, 
granatin B, and geraniin, is through down-regulation of mPGES-1, suggesting that the 
ellagitannins have novel functionality. It can be expected that they can be used to prevent 
and treat several inflammatory disorders without side effects, unlike the cases of existing 
NSAIDs that target COX. There is need of in vivo studies using inflammatory model 
animals to confirm the biological effects.  
 
  
22 
 
 
 
 
 
 
Chapter III 
 
 
Red-kerneled rice proanthocyanidin inhibits 
arachidonate 5-lipoxygenase and decreases 
psoriasis-like skin inflammation 
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Colored rice contains a lot of polyphenols such as anthocyanin and 
proanthocyanidin 42. N. Ganeko et al. recently isolated and identified a proanthocyanidin 
from the hulls of red-kerneled rice (red-kerneled rice proanthocyanidin; RRP) 43. RRP is 
an octamer of catechin with an average molecular weight 2338. Red-kerneled rice is 
reported to have potent antioxidant 44 and anti-inflammatory activities 45. In the present 
study, the mechanism of RRP on 5-LOX and/or LTB4-related inflammation was 
investigated, and confirmed the effect in chronic skin inflammation model mice. 
Psoriasis is a classic type 1 autoimmune disease characterized by chronic skin 
inflammation with scaly erythematous plaques and marked epidermal hyperplasia 46. In 
the pathogenesis of psoriasis, IL-23 facilitates IL-17 production from T helper 17 (Th17) 
cells, leading to epidermal hyperplasia and inflammatory cell infiltration 46,47. In psoriatic 
skin lesions, neutrophils infiltrate the dermis during the early phase 48, and LTB4 
production increases 49. LTB4 plays a role in neutrophil recruitment through the receptor 
BLT1, which is coordinated with CXCR2, a chemokine receptor for CXCL 1/2, in 
imiquimod (IMQ)-induced psoriasis-like skin in mice 50,51. Therefore, 5-LOX inhibitors 
may be useful therapeutic agents for psoriasis. 
In this chapter, it is reported that RRP inhibits 5-LOX, catalyzing the first process 
to produce LTA4 as a precursor of several LTs, and improves IMQ-induced psoriasis-like 
skin as a chronic inflammation 52. 
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MATERIALS AND METHODS 
 
 
Preparation of proanthocyanidin derived from red-kerneled rice 
Red-kerneled rice proanthocyanidin was prepared as described previously 43. 
The rice hulls from red-kerneled rice (Oryza sativa, Red rice company Co., Ltd. Soja, 
Japan) were homogenized with 70% aqueous acetone, and the crude extract was loaded 
onto a column packed with Diaion HP-20 resin. A polyphenol-rich fraction was isolated 
with 50% methanol. Gel permeation chromatography analysis confirmed the presence of 
the RRP catechin octamer (Fig. 7) in this fraction based on its molecular weight. The 
dried RRP was redissolved in 50% ethanol or DMSO for in vivo or in vitro study, 
respectively. 
 
Cell culture and treatment 
Rat basophilic leukemia cell line RBL-2H3 (Japanese Cancer Research 
Resources Bank, Tokyo, Japan), human non–small-cell lung carcinoma cell line A549 
(ATCC CCL-185), and human embryonic kidney (HEK) 293T cell (RIKEN BioResource 
Center, Tsukuba, Japan) were cultured in Roswell Park Memorial Institute medium and 
 
Fig. 7. Chemical structure of RRP. 
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DMEM containing 10% fetal bovine serum, 100 units/mL penicillin, and 100 g/mL 
streptomycin. The cells were maintained at 37°C in a humidified atmosphere of 95% air 
and 5% CO2. RBL-2H3 and A549 cells were incubated for 16 h with 0–10  RRP in 
DMSO or vehicle only as a control. Cell viability was measured using CellTiter-Glo 2.0 
Assay (Promega, Madison, WI, USA). 
 
Enzyme immunoassay 
Arachidonic acid (10 M) and A-23187 (5M) were added to the RBL-2H3 cell 
culture medium to induce LTB4 synthesis, and arachidonic acid (10 M) was added to the 
culture medium of A549 cells to induce PGE2 synthesis. After incubation for 5 min or 30 
min, the concentration of LTB4 or PGE2 in the medium was measured by enzyme 
immunoassay using the LTB4 or PGE2 ELISA Kit (Cayman Chemical Co. Ann Arbor, MI. 
USA) according to the manufacturer’s instructions. 
 
LOX and COX assays 
The enzyme activity of 5-LOX, leukocyte-type 12-LOX, COX-1, and COX-2 
was assayed as described previously 53,54. 5-LOX 55, 12-LOX 56, COX-1 57, and COX-2 
57 were partially purified from RBL-2H3 cells, J774A.1 cells overexpressing porcine 12-
LOX, and COLO320DM cells overexpressing COX-1 and COX-2, respectively. Human 
recombinant 5-LOX was purchased from Cayman Chemical. These enzymes were 
preincubated for 5 min at 4°C with or without RRP and catechin (Sigma-Aldrich, St. 
Louis, MO, USA) and the enzyme reaction started by the addition of 25 M arachidonic 
acid for 5-LOX and 12-LOX or 25 M linoleic acid for COX under optimum reaction 
conditions. The LOX reactions were carried out in the following buffers: 5-LOX, 100 
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mM Tris–HCl (pH 7.4), 2 mM CaCl2, and 2 mM adenosine triphosphate (5 min at 30°C); 
12-LOX, 100 mM Tris–HCl (pH 7.4) (5 min at 30°C). The products were reduced by the 
addition of glutathione peroxidase (0.1 unit) and 5 mM glutathione, followed by 
incubation for a further 20 min. COX-1 and COX-2 were assayed in 100 mM Tris–HCl 
(pH 7.4), 2 M hematin, and 5 mM tryptophan for 5 min at 24°C. After acidification of 
the reaction mixture by the addition of 100 mM HCl, 0.25 nmol of 15-
hydroxyeicosadienoic acid was added as an internal standard. The products were analyzed 
by RP-HPLC using a COSMOSIL 5C18-MS-II column (5 m particle, 4.6 × 250 mm, 
Nacalai Tesque, Kyoto, Japan) with a solvent system of methanol/water/acetic acid 
(80:20:0.01, v/v). Absorption at 235 nm was continuously monitored using a Waters 2489 
UV/Visible detector. The metabolites, 5-hydroxyeicosatetraenoic acid (HETE) in the 5-
LOX reaction, 12- and 15-HETE in the leukocyte-type 12-LOX reaction, and 9- and 13- 
hydroxyoctadecadienoic acid in the COX reaction, were quantified by comparing the area 
under the peak with that of an internal standard. To determine whether RRP chelates 
calcium ions, EDTA was used as a positive control. 
 
PGES assay 
Recombinant human mPGES-1 was used for the PGES assay. HEK293T cells 
were transfected with the expression vector pCMV6-Entry-PTGES (Origene 
Technologies, Inc., Rockville, MD, USA) using Lipofectamine 2000 (Life Technologies, 
Carlsbad, CA, USA) according to the manufacturer’s instructions. After 2 days, the cells 
were scraped off the dishes and disrupted by sonication in 10 mM potassium phosphate 
buffer (KPB), pH 7.2, and the microsome fraction was used as the enzyme source. 
Membrane-bound PGES-2 (mPGES-2) and cytosolic PGES (cPGES) were prepared from 
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the microsomal and cytosolic fractions of A549, respectively. Fraction samples were 
preincubated for 15 min at 4°C with or without RRP and catechin, and mPGES-1 activity 
was initiated by the addition of 80 M PGH2 in 100 mM KPB (pH 7.2) with 2.5 mM 
glutathione and incubated for 1 min at 24°C. mPGES-2 activity was initiated by the 
addition of 40 M PGH2 in 100 mM KPB (pH 6.5) with 1 mM DTT and incubated for 1 
min at 24°C. cPGES activity was initiated by the addition of 100 M PGH2 in 100 mM 
Tris–HCl buffer (pH 8.0) with 2.5 mM glutathione and incubated for 1 min at 24°C. The 
reaction was terminated using 100 mM FeCl2/0.5 M citric acid, and 2.5 nmol of PGB2 
was added as an internal standard. The produced PGE2 was analyzed as described above 
using a solvent system of ACN/water/acetic acid (40:60:0.01, v/v). Absorption at 192 nm 
was continuously monitored. 
 
Psoriasis-like mouse model 
Seven-week-old male BALB/c mice (24–28 g) were purchased from Charles 
River Laboratories, Inc. (Wilmington, MA, USA). Mice were housed under specific 
pathogen-free conditions and had free access to drinking water and food (CRF-1, Oriental 
Yeast Co., Ltd., Tokyo, Japan). Each experimental group had 6 mice. Psoriasis-like mouse 
skin was induced as described previously 52. In brief, 12.5 mg IMQ cream (Beselna cream 
5%, Mochida Pharmaceutical Co., Ltd., Tokyo, Japan) was applied to the ear for 5 
consecutive days (total, 62.5 mg IMQ/mouse). On day 6, the ear thickness was measured 
with a Quick Micro (Mitutoyo Co., Kanagawa, Japan), and the mice were sacrificed. All 
protocols were approved by the Exclusive Committee on Animal Research at Okayama 
Prefectural University, and the study was conducted in accordance with the Public Health 
Service policy. 
28 
 
Dosage information/Dosage regimen 
RRP (50 L/ear/day containing 25, 250, or 2500 g; 0.2, 2, or 20 mM/ear/day, 
i.e., 2, 20, or 200 mg/kg/day) was applied topically to the ear of each mouse 30 min before 
the application of IMQ cream for 5 days. These doses are equivalent to human at 0.16, 
1.62, and 16.2 mg/kg/day converted to take into account the body surface area 58. The 
dose of RRP was determined according to information in another report 59. Throughout 
the experiment, RRP-treated mice presented with no abnormalities and had no significant 
changes in weight or food intake as compared to control mice. 
 
Histopathological and immunohistochemical analyses 
For histological analysis, IMQ-induced mouse ears treated with RRP or vehicle 
were fixed in 100 mM sodium phosphate buffer (pH 7.4) containing 4% (w/v) 
paraformaldehyde and embedded in paraffin. The sections were used for hematoxylin and 
eosin (HE) staining and observed by light microscopy. Changes in spinous layer thickness 
were measured under the microscope. 
For immunohistochemical analysis, the fixed ears were embedded in Tissue-Tek 
OCT compound (Sakura Finetek Japan Co., Ltd., Tokyo, Japan). The sectioned tissues 
were treated with 3% hydrogen peroxide to block endogenous peroxidase activity and 
10% Block Ace (DS Pharma Biomedical Co., Ltd., Tokyo, Japan) to block nonspecific 
binding. For immunolabeling neutrophils, the primary antibody was rat anti-Ly-6G/Ly-
6C (Gr-1) antibody (1:200; catalog no. 108413, lot no. B141536, BioLegend, San Diego, 
CA), and the secondary antibody was FITC-labeled donkey anti-rat IgG (1:400, Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA. USA). The sections were mounted 
using Vectashield mounting medium for fluorescence with 4',6-diamidino-2-phenylindole 
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(DAPI, Vector Laboratories, Inc., Burlingame, CA, USA) and observed by confocal laser 
scanning light microscopy (Fluoview FV1000, Olympus Co., Tokyo, Japan). 
 
Real-time quantitative PCR 
Total RNA was isolated using the RNeasy plus Mini Kit (Qiagen N.V., Hilden, 
Germany), and cDNA was prepared using High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, LLC, Foster City, CA, USA). Quantitative PCR was performed 
using SsoAdvanced Universal SYBR Green Supermix (Bio Rad Labs., Hercules, CA, 
USA) on the StepOnePlus Real-Time PCR System (Applied Biosystems, LLC, Foster 
City, CA, USA), and the following primer pairs: Alox5, 5′-AGCGGCAGCTCA 
GTTTAGAA-3′ (forward) and 5′-GGAACTGGTGTGTACAGGGG-3′ (reverse); Il17a 
(IL-17A), 5′-CAGGGAGAGCTTCATCTGTGT-3′ (forward) and 5′-GCTGAGCTTT 
GAGGGATGAT-3′ (reverse); Il22 (IL-22), 5′-CGTCAACCGCACCTTTAT-3′ (forward) 
and 5′-AGGGCTGGAACCTGTCTG-3′ (reverse); S100a9 (S100a9), 5′-GACACCCTG 
ACACCCTGAG-3′ (forward) and 5′-TGAGGGCTTCATTTCTCTTCTC-3′ (reverse); 
Krt1 (keratin 1), 5′-TTTGCCTCCTTCATCGACA-3′ (forward) and 5′-GTTTTGGG 
TCCGGGTTGT-3′ (reverse); Gapdh (GAPDH), 5′-TGTTCCTACCCCCAATGTGT-3′ 
(forward) and 5′-CCCTGTTGCTGTAGCCGTAT-3′ (reverse). Data were normalized to 
Gapdh expression level. 
 
Electrospray ionization mass spectrometry (ESI-MS) 
Samples were prepared as described previously 60. Mouse ears were homogenized 
using a Polytron homogenizer in 2 mL of ice-cold methanol and incubated at −30°C 
overnight. The lipid components were extracted using the Bligh and Dyer method 61, and 
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the recovery of each lipid throughout the procedure was calibrated against an internal 
added standard of 500 pmol d4-labeled PGE2 or d5-labeled eicosapentaenoic acid. For 
analysis of the fatty acid metabolites LT and PG, lipids were extracted using Oasis HLB 
cartridges (Waters, Milford, MA, USA) and were dried under nitrogen gas. The analysis 
was performed using a 4000Q-TRAP quadrupole-linear ion trap hybrid mass 
spectrometer (AB Sciex, Framingham, MA, USA) with LC (NexeraX2 system; Shimadzu 
Co., Kyoto, Japan). The sample was applied to a C18 column (Kinetex C18, 2.1 × 150 
mm, 1.7 m, Phenomenex, Inc., Torrance, CA, USA) coupled for ESI-MS/MS. For fatty 
acid analysis, the samples were applied to a column and separated using a step gradient 
with mobile phase A (ACN:methanol:water, 1:1:1 (v/v/v) containing 5 M phosphoric 
acid and 1 mM ammonium formate) and mobile phase B (2-propanol containing 5 M 
phosphoric acid and 1 mM ammonium formate) at a flow rate of 0.2 mL/min at 50°C. To 
analyze oxidized fatty acids, the samples are applied to a column and separated using a 
step gradient with mobile phase C (water containing 0.1% acetic acid) and mobile phase 
D (ACN:methanol, 4:1; v/v) at a flow rate of 0.2 mL/min at 45°C. Signature ion fragments 
for each target lipid were monitored and quantified by multiple reaction monitoring 
(MRM). Lipids were identified by the MRM transition 62 and retention times based on 
the peak area of the MRM transition and the calibration curve for an authentic standard 
for each compound. 
 
Statistics 
Data were analyzed using Student’s t-test and Dunnett’s post-hoc test at a 
significance level of p < 0.01.  
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RESULTS 
 
Inhibitory effect of RRP on lipoxygenase and cyclooxygenase activity 
RRP inhibited rat 5-LOX and porcine leukocyte-type 12-LOX activity dose-
dependently, with IC50 values of 7.0 M and 47.5 M, respectively (Fig. 8A). RRP up to 
500 M had no effect on COX-1 or COX-2 activity, whereas catechin monomer inhibited 
rat 5-LOX and COX-1 activity (IC50, 9.0 and 30.0 M, respectively) (Fig. 8D). RRP and 
catechin also inhibited human 5-LOX (IC50, 16.8 and 2.0 M, respectively) (data not 
shown). Michaelis–Menten kinetics (Fig. 8B, E) and Lineweaver–Burk plot analysis (Fig. 
8C, F) of 5-LOX with RRP or catechin, and the changes in Km and Vmax values for 5-LOX 
are shown in Table 1. The data demonstrate that RRP and catechin increased the Km and 
 
Fig. 8. Effect of RRP (A–C) and catechin (D–F) on 5-LOX, 12-LOX, COX-1, and COX-2 
activity. 
5-LOX and 12-LOX were incubated with 25 M arachidonic acid at 30°C for 5 min, and COX-1 
and COX-2 were incubated with 25 M linoleic acid at 24°C for 5 min with RRP (A) or catechin 
(D). Inhibitory effects on the enzymes by RRP or catechin (A and D), and Michaelis–Menten plot 
(B and E) and Lineweaver–Burk plot (C and F) with or without RRP or catechin are shown. 
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decreased the Vmax of 5-LOX activity, indicating that RRP and catechin are mixed 
noncompetitive inhibitors of 5-LOX. Calcium ion is required for 5-LOX activity in vitro 
63,64 and is also essential for translocation of 5-LOX from the cytoplasm to the membrane 
in leukocytes 65. As shown in Fig. 9, the specific activity of 5-LOX was reduced by 
approximately 90% by the addition of EDTA as a calcium ion chelating agent and was 
then restored to the original specific activity by the addition of 200 M CaCl2. In contrast, 
the RRP-induced decrease in 5-LOX activity was not restored by the addition of CaCl2, 
suggesting that the mechanism of RRP inhibition of 5-LOX did not involve chelation.  
Table 1. Km and Vmax values calculated based on Lineweaver–Burk plot against 5-LOX (Fig. 8C, F) 
 
Inhibitor 
M) 
Km 
(M) 
Vmax 
(nmol･min−1･mg−1) 
vehicle 47.6 4.4 
RRP 13 111.1 3.1 
 38 200.0 1.6 
catechin 10 79.7 2.7 
 20 118.5 2.1 
 
 
Fig. 9. Investigation of calcium ion chelate effect. 
5-LOX preincubated with (+) or without (−) 200 M CaCl2 was incubated with 25 M arachidonic 
acid at 30°C for 5 min, in the reaction mixture (100 mM Tris–HCl (pH 7.4), 400 M CaCl2, and 2 
mM adenosine triphosphate) in the presence of Vehicle (1% DMSO) or 10 M RRP or 200 M 
EDTA and the products were quantified using RP-HPLC (n=3). The values represent mean ± SEM. 
*p < 0.01 compared with treatment with EDTA CaCl2 (−). 
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Inhibitory effect of RRP on prostaglandin E synthase 
RRP also dose-dependently inhibited mPGES-1 and cPGES activity, with IC50 
values of 7.7 M and 45.3 M, respectively (Fig. 10A). However, RRP up to 500 M had 
no effect on mPGES-2 activity, and catechin monomer (up to 200 M) had no effect on 
mPGES-1 (Fig. 10D). Michaelis–Menten kinetics and Lineweaver–Burk plot analysis of 
mPGES-1 with RRP (Fig. 10B, C) and the Km and Vmax values of mPGES-1 are shown in 
Table 2. The data show that RRP did not affect the Km but decreased Vmax against mPGES-
1 activity, indicating that RRP is a noncompetitive inhibitor of mPGES-1. 
 
RRP decreases LTB4 and PGE2 release from intact cells 
Pretreatment of RBL-2H3 and A549 cells with RRP dose-dependently decreased 
LTB4 and PGE2 production (Fig. 11A and C). To exclude the possibility of RRP 
cytotoxicity, it was investigated the effect of RRP on cell viability (Fig. 11B and D). 
Under the experimental conditions used to assess LTB4 and PGE2 production, cell 
viability was determined to be >90% (Fig. 11B and D). 
 
Morphological improvements in IMQ-induced skin inflammation by RRP 
 The histological effects of RRP on IMQ-induced psoriasis-like skin were 
investigated. HE staining showed that IMQ-treated mouse ears had a thickened spinous 
layer and increased infiltration of inflammatory cells compared with normal controls (Fig. 
12A). Topical application of RRP (25–2500 g/ear) dose-dependently suppressed the 
hyperplasia and decreased inflammatory cell infiltration. Immunohistochemical staining 
indicated that IMQ-treated mouse ears had more infiltrating neutrophils than did normal 
controls. The application of RRP (2500 g/ear) markedly decreased neutrophil infiltration  
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Table 2. Km and Vmax values calculated based on Lineweaver–Burk plot against mPGES-1 
Inhibitor 
M) 
Km 
(M) 
Vmax 
(nmol･min−1･mg−1) 
vehicle 125.0 217.4 
RRP 10 125.0 156.3 
 20 125.0 95.2 
 
 
Fig. 10. Effect of RRP and catechin on PGES activity. 
mPGES-1 and mPGES-2, cPGES were incubated with 80 and 40, 100 M PGH2 at 24°C for 1 min 
in the presence of RRP (A), and mPGES-1 in the presence of catechin (D) at various concentrations 
and the products were quantified using RP-HPLC. Relative enzyme activities as compared with the 
activity without inhibitor are shown. Kinetic analysis of mPGES-1 inhibition by RRP was incubated 
with various concentrations of PGH2 at 24°C for 1 min in the absence of indicated concentrations 
of RRP. Michaelis−Menten plot (B) and Lineweaver−Burk plot (C) are shown. 
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(Fig. 12B). As shown in Fig. 12C, the ear thickness, as measured by micrometer, and 
spinous layer thickness, as measured by microscopy, significantly decreased to 
approximately 30% and 50%, respectively, of IMQ-treated ears after treatment with RRP 
(250 and 2500 g/ear); the number of infiltrating neutrophils decreased significantly to 
about 10% of that of with IMQ-treated ears (Fig.12C). Treatment with catechin monomer 
(0.1 mol; corresponding to 250 g/ear RRP) resulted in no significant changes in ear 
thickness (Fig. 12C).  
 
 
 
 
 
Fig. 11. Effect of RRP on LTB4 or PGE2 production and cell viability in RBL-2H3 or A549. 
LTB4 (A) and PGE2 (C) production were measured by ELISA (n=3). Cells were treated with 0−10 
M RRP, and viability was assessed after 16 h using CellTiter-Glo 2.0 Assay on RBL-2H3 (B) and 
A549 (D) cells (n=4). The values represent mean ± SEM. *p < 0.01 compared with treatment with 
0 M RRP. 
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Changes in psoriasis-associated mRNA expression in IMQ-induced mouse 
skin 
The expression of several psoriasis-related mRNAs in IMQ-induced mouse ears 
was investigated. The mRNA expression of Alox5 (5-LOX), cytokines produced by Th17 
cells Il17a (IL-17a) and Il22 (IL-22), and markers of keratinocyte differentiation or 
activation S100a9 (S100a9) and Krt1 (Krt1) was analyzed by quantitative PCR (Fig. 13). 
Il17a and Il22 mRNAs were markedly increased by IMQ treatment as compared to 
untreated mice (no expression). S100a9 and Krt1 increased approximately 5000-fold and 
20-fold, respectively, compared with untreated mice. The IMQ-induced expression of 
Il17a, Il22, S100a9, and Krt1 was dose-dependently suppressed by RRP. The expression 
of Alox5 did not change with RRP treatment. 
 
Changes in eicosanoid production in IMQ-induced mouse skin 
The production of LTB4, 12-HETE, arachidonic acid, PGD2, PGE2, and PGF2 
in mouse ears as determined by ESI-MS is shown in Fig. 14. The eicosanoids were 
increased by IMQ treatment. RRP treatment dose-dependently decreased LTB4 in IMQ-
induced mouse skin, reaching the level of LTB4 production of normal mouse skin at a 
dose of 2500 g/ear. In addition, 12-HETE production decreased significantly at a dose 
of 250 g/ear RRP. In contrast, RRP treatment (2500 g/ear) significantly increased PGD2 
and PGE2 production. No significant differences were observed in the production of 
arachidonic acid or PGF2α, and the amounts of the other eicosanoids, including PGI2, 
thromboxane A2, and cysteinyl-LTs (LTC4, LTD4, and LTE4), were very low or 
undetectable. 
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Fig. 12. Histological and histochemical analyzes in mouse ear. 
Histological changes after RRP treatment were observed in HE staining (A) and immunofluorescent 
staining of Ly-6G/Ly-6C (green, Gr-1 as a neutrophil marker) and DAPI (blue, nuclear 
counterstain) (B). Ear thickness was measured by Quick Micro, and spinous layer thickness was 
measured under the microscope (upper graphs in C). Infiltrating cells and neutrophils were counted 
with HE staining and Ly-6G/Ly-6C immunofluorescent staining, respectively (lower graphs in C). 
Double-headed arrows indicate hyperplasia of stratum spinosum; arrowheads indicate infiltrating 
cells (A) and neutrophils (B). Data are presented as the mean ± SEM. *p < 0.01 vs. IMQ-induced 
control. 
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Fig. 13. Changes in psoriasis-associated mRNA expression in IMQ-induced mouse skin. 
Expression levels of Alox5 (5-LOX), Il17a (IL-17a), Il22 (IL-22), S100a9 (S100a9), and Krt1 
(Krt1) were normalized to that of Gapdh (GAPDH). Relative expression of Il17a and Il22 is shown 
vs. that of IMQ-treated mice; those of the other genes are shown vs. normal control. Data are 
presented as the mean ± SEM of 6 mice per group. *p < 0.01 compared with the IMQ-induced 
control. n.d., not detected. 
 
Fig. 14. Changes in eicosanoid production. 
The production of LTB4, 12-HETE, arachidonic acid, PGD2, PGE2, and PGF2 were analyzed by 
ESI-MS. Data are presented as the mean ± SEM of 6 mice per group. *p < 0.01 vs. IMQ-induced 
control. 
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DISCUSSION 
 
 
RRP exhibited potent mixed noncompetitive inhibition of 5-LOX, with an IC50 
of 7.0 M. RRP decreased LTB4 production in RBL-2H3 cells. Topical application of 
RRP to IMQ-induced psoriasis-like mouse skin suppressed hyperplasia, decreased 
inflammatory cell infiltration, down-regulated expression of the psoriasis-associated 
genes Il17a, Il22, S100a9, and Krt1, and decreased the production of LTB4 but no other 
arachidonate metabolite. 
In the pathogenesis of IMQ-induced psoriasis, IL-17 and IL-22 produced by 
Th17 cells induce the expression of a variety of proinflammatory mediators and induce 
epidermal proliferation 66,67. In human psoriasis, the number of Th17 cells is elevated, 
and the level of IL-17 and IL-22 expression correlates with disease severity 68. The 
involvement of IL-17 in neutrophil-mediated inflammation suggests that neutrophils may 
also be involved in the pathogenesis of psoriasis 69. 5-LOX, predominantly expressed in 
neutrophils 70, produces LTB4, which then binds to its receptor BLT1 to exert a variety of 
effects 71. BLT1 and CXCR2 coordinately promote neutrophil infiltration into psoriatic 
skin. IL-1 produced by neutrophils then promotes IL-19 production in keratinocytes, 
leading to acanthosis 51. The migration of neutrophils in IMQ-induced psoriasis-like skin 
is reduced in BLT1 knockout mice, and the psoriatic condition is improved 51. Thus, 
LTB4-BLT1 signaling leads to neutrophil migration and contributes to the induction of 
psoriatic symptoms 49. The present results show that RRP inhibited 5-LOX in vitro (Fig. 
8), suppressed LTB4 levels in vivo (Fig. 14), and reduced epidermal proliferation and 
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neutrophil infiltration (Fig. 12). These findings suggest that RRP treatment markedly 
decreases psoriatic symptoms via 5-LOX inhibition. 
PGE2 produced by COX-2 and mPGES-1 binds to the EP2 and EP4 receptors on 
Th17 cells, driving psoriatic inflammation 72. It was observed that RRP inhibited mPGES-
1, the terminal enzyme in PGE2 synthesis, but increased the production of the 
proinflammatory lipid mediators PGE2 and PGD2 (Fig. 14). Because of the dominant 
effect of 5-LOX inhibition by RRP, COX likely plays a role in maintaining the metabolic 
balance in this pathway. Although the value of RRP inhibition of mPGES-1 in vivo is yet 
unproven, these observations suggest that RRP may exert therapeutic activity on psoriatic 
inflammation. 
While recent studies have reported the amelioration of IMQ-induced psoriasis-
like skin by the phytochemicals paeoniflorin 73,74, isoflavone 75, rhododendrin 59, 
epigallocatechin-3-gallate 76, and curcumin 77, none of the reports elucidate the 
mechanism underlying the observed effects on psoriatic inflammation. This is the first 
report that a natural compound improves psoriatic inflammation by decreasing the 
production of LTB4 by 5-LOX. In fact, RRP not only inhibited 5-LOX without a chelating 
effect but also decreased LTB4 release from intact RBL-2H3 cells (Fig. 8, 9, 11). While 
the absorption efficiency and pharmacokinetics of RRP remain unknown, the 
bioavailability of proanthocyanidin has been addressed in several reports. Using an ex 
vivo gut lumen model, S. Deprez et al. observed that the proanthocyanidin polymer can 
be absorbed into the luminal epithelium 78. T. Shoji et al. report that the apple procyanidin, 
including the octamer, is absorbed and can be detected in plasma after oral administration 
of apple procyanidin oligomers to rats 79. In the present findings, similar in vitro inhibition 
of 5-LOX by catechin monomer and RRP (catechin octamer) was observed. However, the 
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monomer was not effective in decreasing symptoms in the psoriasis-like skin model in 
vivo, indicating that the catechin octamer is more useful than the monomer as a 
therapeutic agent. The IC50 of RRP for 5-LOX inhibition (7 M) (Fig. 8A) is comparable 
to that of several known 5-LOX inhibitors, including baicalein 80, oleuropein 81, and 
eupatilin 82. However, few studies address inhibition patterns and in vivo studies, and none 
address the possible calcium ion chelating effect of these compounds. In this study, the 
findings ruled out the possibility of such an effect by RRP (Fig. 9). 
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Chapter IV 
 
 
Conclusion Remarks 
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PGE2 and LTs are the most important pro-inflammatory lipid mediators among 
eicosanoids. They induce acute inflammation, and if the effects are excessive and 
sustained they make chronic inflammatory disorders including dermatitis, asthma, cancer, 
and neurodegeneration. Preventing chronic inflammation, the medication inhibiting PGE2 
and LTs production is considered important. Actually, NSAIDs are used clinically as COX 
inhibitors to decrease PGE2 production, but they have gastrointestinal and cardiovascular 
side-effects. Zileuton, 5-LOX inhibitor, also has problems such as liver toxicity. It is truly 
significant to explore the substances without side effects. In the present study, some 
compounds derived from natural products were found.  
Ellagitannins isolated from pomegranate leaves, granatin A and granatin B, and 
the structural analog, geraniin, selectively suppressed mPGES-1 expression without 
affecting COX-2 in non-small cell lung carcinoma A549 cells. The ellagitannins also 
down-regulated TNF, iNOS, and anti-apoptotic factor Bcl-2, and induced A549 cells to 
undergo apoptosis. These findings indicate that the ellagitannins may have anti-
inflammatory and anti-carcinogenic effects, due to their specific suppression of mPGES-
1 without side effects by COX inhibition. 
Proanthocyanidin isolated from red-kerneled rice inhibited mPGES-1 (IC50 7.7 
M) with noncompetitive inhibition and 5-LOX (IC50 9.0 M) with mixed 
noncompetitive inhibition. The proanthocyanidin decreased PGE2 and LTB4 production 
in A549 cells and RBL-2H3 cells, respectively. In IMQ-induced psoriasis-like mouse skin 
which LTB4 is deeply involved, a topical application of the proanthocyanidin significantly 
decreased LTB4 production in the skin causing to suppress hyperplasia, decrease 
inflammatory cell infiltration, and down-regulate the psoriasis-associated genes. These 
results increase our understanding of the mechanism underlying the anti-inflammatory 
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effect of the proanthocyanidin. The compound may prove to have therapeutic effects on 
5-LOX and/or LT-related disorders. 
Taken together, this study reveals that pomegranate leaf-derived ellagitannins 
and red-kerneled rice-derived proanthocyanidin have inhibitory mechanism of pro-
inflammatory lipid mediator synthesis and function for prevention or improvement of 
chronic inflammation.  
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